Arrowhead Tackles Two Targets To Lower Multiple ASCVD-Causing Lipids
Early clinical data for ARO-DIMER-PA, the first-ever dual-functional RNAi therapeutic, provide initial validation for the company’s approach to silencing two genes at once – in this case, PCSK9 and APOC3.
Scrip - September 15, 2026

Phase II Depression Failure May Close Door On Contineum/J&J’s M1 Antagonist
Phase II miss in MDD comes less than a year after Phase II failure with the same drug in multiple sclerosis. Analysts say Contineum’s primary value lies in its Phase II IPF candidate, PIPE-791.
Scrip - September 15, 2026

Vera’s Trutakna Gains Early Market Share As Phase III IgAN Data Put It On Par With Voyxact
Analysts suggested the efficacy of Trutakna looks overall consistent with its closest competitor, Otsuka’s Voyxact, but more detailed data should help differentiate the two.
Scrip - September 15, 2026

Legend Appoints Ingrid Zhang To Usher In Next Cell Therapy Era
While Carvykti has lots of growth span ahead of it, the former Novartis executive will be tasked with building Legend’s next big growth opportunity.
Scrip - September 15, 2026

WCLC 2026: BioNTech’s Gotistobart Looks Closer To Big Win In NSCLC
The next-generation CTLA-4 inhibitor has extended overall survival in hard-to-treat second-line NSCLC but needs to replicate the results in the pivotal stage of PRESERVE-003.
Scrip - September 15, 2026

Stock Watch: Rookie Mistakes In Product Valuation
Pharmaceutical product valuation needs assumptions that include market share, compliance and diagnosis rates. These need to be validated rather than assumed to be maximal and fixed over the forecast period.
Scrip - September 15, 2026

GSK Taps Chimagen To Enter Trispecific Multiple Myeloma Territory
Deal Snapshot: The UK major is linking up again with the Chinese group, this time buying a preclinical trispecific T cell-engager that it plans to develop for multiple myeloma.
Scrip - September 15, 2026

Definium’s Second Anxiety Trial Win Pushes Psychedelic Race Into Final Stretch
DT120 cut anxiety scores 5.1 points more than placebo in its second positive GAD trial, clearing Definium's path toward a first-half 2027 FDA filing.
Scrip - September 15, 2026

BioVie Plans Phase III Study After Long COVID Drug Shows Subgroup Signals
The company’s next move will depend on whether subgroup signals can survive a confirmatory trial.
Scrip - September 15, 2026

WCLC 2026: Ivonescimab OS Win Sets High Bar For Other Keytruda Rivals In 1L NSCLC
In the China-only HARMONi-2 study versus Keytruda, Akeso's bispecific ivonescimab extended median OS by 8.2 months to 30.75 months versus Keytuda alone in PD-L1-positive NSCLC in the first-line setting.
Scrip - September 15, 2026

Medtronic Moves to Complete MiniMed Separation
Medtronic launched an exchange offer to divest at least 80.1% of MiniMed, formerly Medtronic's diabetes business. The offer expires Oct. 9. MiniMed reported fourth-quarter revenue of $837m, up 15.6%, while projecting approximately 10% organic growth in fiscal 2027.
Medtech Insight - September 15, 2026

Cardiac AI: EU Needs To Rethink Metrics For Success, JRC Says
The Joint Research Centre ranks cardiac AI tools for readiness and impact and recommends the EU take a more nuanced approach to assessment.
Medtech Insight - September 15, 2026

US FDA Warning To Bausch + Lomb Suggests Potential For Recall, Production Interruption
Warning letter explains that both Rx and OTC products are made at B+L facility FDA officials inspected in March. FDA twice notes that recall would be needed if firm’s response to the warning isn’t satisfactory.
HBW Insight - September 16, 2026

Glenmark Ahead Of Schedule With A Ryaltris Launch In Brazil
Glenmark's Ryaltris has reached Brazil ahead of schedule, bringing the allergy nasal spray to what the firm describes as the largest healthcare market in Latin America.
Generics Bulletin - September 15, 2026

AAM Report Trumpets Savings But Carries Warnings Of Industry Doom
While celebrating the near half-trillion dollars in US savings achieved by using generics and biosimilars in 2025, the AAM’s latest report also warned that the sustainability of the generics industry was “in peril” as structural deflation risked causing the sector to “shrink beyond repair.”
Generics Bulletin - September 15, 2026

Handa Secures Cabozantinib Approval After Exelixis Fails To Block 505(b)(2) Pathway
Handa’s Omcazio hybrid drug has won final US approval after Exelixis dropped its patent suit and failed to persuade the FDA to block the 505(b)(2) product, opening another route into the blockbuster cabozantinib market.
Generics Bulletin - September 15, 2026

Mylan Facing Stern Test To Keep Delayed Humana Trial At Bay
Humana is seeking to lift a 45-day stay on its generic price-fixing bellwether against Mylan and Lannett, as the parties clash over whether special discovery master Lawrence Stengel should remain involved in the litigation.
Generics Bulletin - September 15, 2026

Trump’s MFN Deals Reach 89% Of US Market As Benchmarking And Durability Remain In Doubt
The voluntary deals now reach most of the US branded market even as the scope of each agreement remains somewhat opaque. Meanwhile, the foreign price increases the policy implicitly relies on have refused to materialize.
In Vivo - September 16, 2026